Adicet Bio Inc (ACET)

Currency in USD
0.650
-0.037(-5.40%)
Real-time Data·
ACET Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
ACET is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.6210.690
52 wk Range
0.4471.640
Key Statistics
Prev. Close
0.687
Open
0.68
Day's Range
0.621-0.69
52 wk Range
0.447-1.64
Volume
2.11M
Average Volume (3m)
497.64K
1-Year Change
-48.73%
Book Value / Share
1.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACET Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.600
Upside
+761.54%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Adicet Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Adicet Bio Inc Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio Inc SWOT Analysis


Gamma-Delta Frontie
Adicet Bio pioneers engineered gamma-delta T cell therapies, aiming to revolutionize treatment for autoimmune diseases and cancers amid fierce competition
Financial Tightrope
With $176.3M cash but no revenue, Adicet faces a critical period. Its robust financial health score of 1.57 underscores the urgency of clinical success
Pipeline Promise
Key trials for lupus nephritis and renal cell carcinoma approach crucial 2025 readouts, with FDA fast-track status highlighting potential market impact
Market Valuation
Analysts maintain a cautious "Market Perform" outlook. Positive trial results could transform Adicet's $65.5M market cap and industry standing
Read full SWOT analysis

Compare ACET to Peers and Sector

Metrics to compare
ACET
Peers
Sector
Relationship
P/E Ratio
−0.5x−3.1x−0.5x
PEG Ratio
−0.01−0.070.00
Price/Book
0.3x1.2x2.6x
Price / LTM Sales
-7.2x3.3x
Upside (Analyst Target)
-355.4%43.4%
Fair Value Upside
Unlock17.7%7.1%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.600
(+761.54% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.34 / -0.3114
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ACET Income Statement

People Also Watch

178.77
ALAB
+4.61%
3.775
PRME
+2.58%
82.4950
NEGG
+38.79%
4.135
ATAI
-0.36%
68.87
ABVX
-1.64%

FAQ

What Stock Exchange Does Adicet Bio Trade On?

Adicet Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Adicet Bio?

The stock symbol for Adicet Bio is "ACET."

What Is the Adicet Bio Market Cap?

As of today, Adicet Bio market cap is 53.84M.

What Is Adicet Bio's Earnings Per Share (TTM)?

The Adicet Bio EPS (TTM) is -1.29.

When Is the Next Adicet Bio Earnings Date?

Adicet Bio will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is ACET a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Adicet Bio Stock Split?

Adicet Bio has split 1 times.

How Many Employees Does Adicet Bio Have?

Adicet Bio has 152 employees.

What is the current trading status of Adicet Bio (ACET)?

As of 08 Aug 2025, Adicet Bio (ACET) is trading at a price of 0.65, with a previous close of 0.69. The stock has fluctuated within a day range of 0.62 to 0.69, while its 52-week range spans from 0.45 to 1.64.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.